Aktis Oncology develops radiopharmaceutical cancer treatments that deliver radioactive material directly to tumors. AKTS reports earnings on Thu, Nov 12, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 2 | Wedbush | Reiterated | Buy | |
| Sep 9 | Oppenheimer | Initiated | Buy | |
| Aug 19 | Wedbush | Initiated | Buy | |
| Aug 19 | BMO Capital | Initiated | Buy | |
| Jul 14 | JP Morgan | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in AKTS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKTS is in one of them and how their past AKTS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AKTS in an article yet. Here's the latest on the wider market.
About Aktis Oncology
Aktis Oncology is a company based in Boston that develops radiopharmaceuticals, which are cancer treatments that carry radioactive material directly to tumors. Its main focus is a platform built on small engineered proteins that bind to targets on cancer cells. Its lead candidate targets Nectin-4, a protein found on several solid tumor types, and is being tested in clinical trials for urothelial cancer and other tumors. The company works with isotope suppliers and contract manufacturers to supply these treatments to cancer patients and their doctors.
- Headquarters
- Boston, MA